Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”

Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2 young women showing malignant pleural effusion secondary to advanced ALK-rearranged lung adenocarcinoma. This report shows that for patients with EGFR mutations in advanced lung adenocarcinoma-associated malignant pleural effusion, complete response to EGFR TKI inhibitor can be observed mostly if pleural effusion and primary lung adenocarcinoma show the same EGFR mutation status.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel” ; volume:14 ; number:3 ; year:2021 ; pages:1616-1620 ; extent:5 ; Case reports in oncology ; 14, Heft 3 (2021), 1616-1620 (gesamt 5)

Contributors, Places and Time

• Creator: Caterino, Umberto ; Cesaro, Cristiano ; Zamparelli, Enzo ; Cesaro, Flavio ; Palma, Alba ; Lucci, Raffaella ; Imitazione, Pasquale ; Casazza, Dino ; Amore, Dario

Further information

• DOI: 10.1159/000520127
• URN: urn:nbn:de:101:1-2022011223425921509435
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:25 AM CEST